水飞蓟宾乙酰化物的选择性合成

在加热条件下,冰醋酸选择性地对水飞蓟宾分子中的醇羟基进行乙酰化,合成了23-O-乙酰水飞蓟宾和3,23-二-O-乙酰水飞蓟宾,其结构经UV,1H NMR,IR和MS表征.     

基于肿瘤靶向的水飞蓟宾-氨基酸席夫碱的合成及性质研究

以水飞蓟宾和氨基酸为原料,通过常规方法合成了一系列具有靶向性的水飞蓟宾-氨基酸席夫碱,并对其抗肿瘤作用进行研究.采用核磁共振碳谱、质谱和红外光谱对已合成的水飞蓟宾-氨基酸席夫碱(氨基酸=甘氨酸(1)、丙氨酸(2)、赖氨酸(3)、苯丙氨酸(4)、谷氨酸(5)、半胱氨酸(6))进行结构表征.采用MTT法对化合物1-6及水飞蓟宾进行抗肝癌细胞SMMC-7721的活性研究,抑制率分别为70.2%,53.7%,47.8%,55.6%,49.2%,51.8%,33.3%.体外抗肿瘤活性实验表明,水飞蓟宾-氨基酸席夫碱系列化合物对人肝癌细胞株SMMC-7721均有抑制作用,且明显高于水飞蓟宾母核.实现了以氨基酸为载体,将具有抗肿瘤活性的天然药物靶向运输至癌细胞内,极具肝靶向药物开发潜力.     

新型水飞蓟宾乙酰阿魏酸单酯的合成

以水飞蓟宾和阿魏酸为起始原料,采用酰氯酯化法合成了新化合物水飞蓟宾-23-乙酰阿魏酸单酯{3-(4-乙酰基.3-甲氧苯基)-2-丙烯酸[3-(4-羟基-3-甲氧基苯基)-6-(3,5,7-三羟基-4-氡代-苯并吡喃-2)-2,3-二氢-1,4-苯并二氧六环-2]-甲基酯},其结构经UV,1H NMR和ESI-MS表征.     

齐墩果酸衍生物的合成及抗肿瘤活性研究

以天然产物齐墩果酸为先导化合物,经过氧化、酯化(酰化)、水解等反应合成了8个齐墩果酸衍生物,以MCF-7和A549细胞为靶细胞,紫杉醇和吉非替尼为阳性对照物,采用磺酰若丹明B(SRB)法进行初步的体外抗肿瘤活性筛选。结果表明,化合物5a对A549细胞的抑制作用与母体齐墩果酸相当,化合物5d对A549细胞的抑制活性明显高于母体齐墩果酸。因此,化合物5a和5d值得进一步研究。     

N-苄氧羰基-甘氨酸水飞蓟宾单酯的合成及其抗氧化活性

以水飞蓟宾(1)与N-苄氧羰基-甘氨酸为起始原料,采用DCC/DMAP促进偶合法合成了新型的N-苄氧羰基-甘氨酸-3-水飞蓟宾酯(2),其结构经UV,1H NMR,IR和ESI-MS表征。采用化学和生物学模型考察了2的清除自由基能力和抗脂质过氧化能力。结果表明,在测定浓度范围内,2具有较好的清除自由基能力和抗脂质过氧化能力。     

基于HER_2受体的新型喹唑啉衍生物的合成及其抗肿瘤活性

以取代4-[(4-硝基苯氧基)亚甲基]哌啶为原料,经还原、取代、suzuki和加成4步反应合成了6个新型的喹唑啉衍生物(5a~5f),其结构经1H NMR和ESI-MS表征。用MTT法考察了5a~5f对人脐静脉内皮细胞(HUVEC),人肺癌细胞(A-549),乳腺癌细胞(MCF-7)和人早幼粒白血病细胞(HL-60)的体外活性抑制活性。结果表明:环丙基【4-【【4-【【6-【5-{[(2-甲磺酰基乙基)氨基]甲基}呋喃-2-基】喹唑啉-4-基】氨基】苯氧基】甲基】哌啶-1-基】甲基酮(5b)抑制活性最好,其IC50分别为0.55μg·m L-1,0.18μg·m L-1,0.27μg·m L-1和5.24μg·m L-1,优于阳性对照药拉帕替尼。     

氯硝柳胺衍生物的合成及抗肿瘤活性研究

以氯硝柳胺为起始原料,经醚化、亲核取代反应得到目标化合物,采用MTT法考察所合成化合物对人类乳腺癌细胞(MDA-MB-231)和人类胰腺癌细胞(ASPC-1)的体外抗肿瘤活性。合成了5个氯硝柳胺衍生物,其结构均经IR、1H-NMR、13C-NMR和MS确证。初步的体外抗肿瘤活性结果显示目标化合物9b和9c的抗肿瘤活性强于阳性对照药,其中化合物9b的活性对所测两种肿瘤株的抑制活性均强于阳性对照药,展现出较强的应用前景。     

靶向VEGFR受体抑制剂齐墩果酸衍生物的合成及初步抗肿瘤活性研究

以天然产物齐墩果酸为母体,设计合成齐墩果酸衍生物,采用计算机辅助药物设计,对C-3、C-28位结构改造,设计合成12个未见文献报道的靶向VEGFR受体抑制剂; 采用噻唑蓝(MTT)法,用人肝癌细胞(HepG2)和乳腺癌细胞(MCF-7)对其进行初步体外抗肿瘤活性筛选;其结构经1H-NMR、13C-NMR谱确证。活性测试得出化合物I7、II1与阳性对照药相比有较强抑制作用,其抗肿瘤活性高于母体OA,分子对接结果显示I7和II1 与 VEGFR 受体具有较好的结合能力,值得进一步研究。     

金诺芬衍生物的合成及抗肿瘤活性

设计合成了一类新型金诺芬衍生物, 采用核磁共振波谱(NMR)和高分辨质谱(HRMS)确认了其结构. 以目标化合物处理肿瘤细胞后, 采用四氮唑蓝盐(MTS)法检测细胞增殖情况, 用流式细胞仪检测细胞凋亡情况, 采用蛋白质免疫印迹(Western blot)法检测总的泛素化蛋白(Ub-Prs)、 K48 位链接多聚泛素化蛋白以及蛋白酶体外源性特异性底物(GFPu)的表达情况. 结果表明, 金诺芬衍生物可通过抑制蛋白酶体功能来发挥抗肿瘤效果.     

一种黄酮衍生物的合成及其体外抗癌活性

以柚皮素为原料,通过对其结构进行修饰,合成了黄酮衍生物5-羟基-2-(4-羟基苯基)-7-(2-吗啉基乙氧基)-4H-苯骈吡喃-4-酮;利用核磁共振、元素分析及质谱确认了产物的结构,利用MTT法测定了其对人肝癌细胞(HepG2)、7721以及QSG7701正常肝细胞株的抑制率.结果表明,同槲皮素相对照,合成的黄酮衍生物对肝癌细胞具有良好的抑制活性.     

一种萘酰亚胺衍生物的合成及其体外抗癌活性测定

合成了萘酰亚胺衍生物2-[2-(二甲基氨基)乙基]-6-2-(2-羟乙胺基)乙胺基-1H-苯并异喹啉-1,3(2H)-二酮;利用元素分析、核磁共振谱及质谱分析了其组成和结构;利用MTT法测定了其对人肝癌细胞(HepG2)、人乳腺癌细胞(MDA-MB-231)及人结肠癌细胞(HCT-116)的体外活性.结果表明,标题化合物的体外抗肿瘤活性优于对照品氨萘非特.     

熊果酸C-3,C-28位衍生物的合成及其抗肿瘤活性研究

以天然产物熊果酸为原料,经过氧化、酰化、酯化等反应合成了11个未见报道的熊果酸衍生物,其结构经过MS、1H NMR及元素分析确定。以氟尿嘧啶和吉非替尼为阳性对照药,经MTT法对A549和SGC-7901细胞进行初步体外抗肿瘤活性研究。结果表明,目标化合物对两种细胞株的抑制率均明显高于母体化合物,且化合物4b和5a的抑制效果高于阳性对照药,值得进一步研究。     

芹菜素衍生物的合成及抗肿瘤活性研究

以芹菜素为起始原料,在C-5、C-6、C-7、C-4′位置上引入甲基、苄基、乙酰基、对甲苯磺酰基、三异丙基硅烷基等多种单元结构基团,合成了16个芹菜素衍生物,采用CCK-8的方法考察了所合成化合物对人肝癌细胞(Hep3β)、人结肠癌细胞(LOVO)、人肺癌细胞(A549)的抑制作用。结果显示,经过化学修饰后的部分化合物比芹菜素有更强的抗肿瘤活性,其中化合物13对人肺癌细胞(A549)的抑制率超过了顺铂,值得进一步探讨和研究。     

姜黄素类似物合成与体外抗肿瘤活性研究

以芳香醛、4-哌啶酮为原料,Claisen-Schimidt缩合制备3,5-(E)-二亚苄基哌啶-4-酮类化合物.采用MTT法测试目标化合物对人类慢性粒细胞白血病急变细胞K562,人结肠癌细胞SW1 116增殖的抑制活性.化合物1-19的结构经核磁和质谱确证,化合物7、10、11对SW1 116的抑制活性比EF-24强...     

Synthesis and in vitro antitumor activity of novel naphthyridinone derivatives

A series of naphthyridinone derivatives based on la(a precursor of Voreloxin) were designed and synthesized.Seven compounds having 70%inhibition against HL60 at 30 μmol/L were further evaluated for their in vitro antitumor activity by SRB assay.Results reveal that thiazol-2-yl and 3-aminomethyl-4-benzyloxyimino-3-methylpyrrolidin-l-yl groups are optimal at the N-1 and C-7positions of naphthyridinone core,respectively.10 j exhibits broad-spectrum activity(IC_(50):0.5-6.25 μmol/L) against all of the tested cell lines including Etoposide- and/or la-resistant ones,and is 1.3-fold to 100-fold more potent than the two references against eight of these cell lines.     

Synthesis and in vitro antitumor activity of novel diaryl urea derivatives

A series of novel diaryl ureas containing 4-[（2-amino-6-trifluromethyl）pyrimidine-4-yl]piperazine-l-yl group were synthesized and evaluated for their cytotoxic activities in a panel of human cancer cell lines. Compared with the reference drug Sorafenib,some compounds showed more potent and a broader spectrum of anti-cancer activities.Among them,compound 2p demonstrated significant inhibitory activities against MDA-MB-231,HT-29 and MCF-7 cell lines with IC₅₀ values of 0.016,0.63,0.001μmol/L, respectively.     

Synthesis and in vitro antitumor activity of substituted anthracene-1,4-diones

Based on a rational approach, 6-substituted 1,4-anthracenediones were synthesized and found to exhibit potent cytotoxic activity against murine and human leukemic cells. The synthetic sequence includes a double Friedel-Crafts reaction, reductive quinone formation, and selective bromination of the alkyl side chain. A key intermediate, 6-bromomethyl-1,4-anthracenedione (10), was synthesized and converted to various active antitumor agents, including a water-soluble phosphate ester pro-drug. The interconversion reactions include displacement of the bromide with various nucleophiles and basic hydrolysis to the alcohol and subsequent oxidation to provide the aldehyde. Based on their ability to decrease L1210 and HL-60 tumor cell viability, 1,4-dihydroxyanthraquinones are inactive but 1,4-anthracenediones have interesting antitumor activity, which may be abolished by modification of the A-ring and improved by substitution of the C-ring. The cytostatic and cytotoxic activity of the representative compound 10 was verified at the National Cancer Institute in studies on the 60-human tumor cell line panel in the in vitro antitumor screening. A wide spectrum of tumor cells are sensitive to 10 inhibition, and concentrations required to inhibit tumor cell growth by 50% (GI₅₀) at 48 h are <10 nM in HL-60 and MOLT-4 and 37.1 nM in SR leukemia. Preliminary studies suggest that the molecular targets and mechanisms of action of 10 may be different from those of daunomycin.     

Synthesis and in vitro antitumor activity of phthalimide-based polymers containing camptothecin

To improve the therapeutic efficacy of 20(s)-camptothecin (CPT) polymeric drugs containing CPT have been designed. A new CPT-conjugate, 3,6-endo-methylene-1,2,3,6-tetrahydrophthalimidoacetamidoglycine camptothecin ester (ETPA-gly-CPT), was synthesized by linking its hydroxyl group to the phthalimido monomer through a glycine-glycine spacer. Its homo- and copolymer with acrylic acid (AA) were prepared by photopolymerization using 2,2-dimethoxy-2-phenylacetophenone (DMP) as a photoinitiator. The monomer and its polymers were characterized by IR, ¹H- and ¹³C-NMR spectra. The ETPA-gly-CPT content in poly(ETPA-gly-CPT-co-AA) obtained by elemental analysis was 40 wt.%. The number-average molecular weights of the polymers determined by gel permeation chromatography were as follows: M_n=15,000 for poly(ETPA-gly-CPT), M_n=18,700 for poly(ETPA-gly-CPT-co-AA). The IC₅₀ values of ETPA-gly-CPT and its polymers against cancer cells were much larger than that of CPT.     

Synthesis and in vitro biological evaluation of novel 2-aminoimidazolone derivatives as anti-tumor agents

Novel 2-aminoimidazolone derivatives were synthesized.Most compounds displayed strong anticancer activities against human carcinoma cells in vitro.Compounds 8a,8b and 8j exhibited optimal activity superior to 5-FU in most cancer cells tested.Especially,the lC₅₀s of 8b（12.6-21.5μmol/L） against five tumor cells were 1 -4 fold less than those of 5-FU（18.4-56.1μmol/L） in vitro.Furthermore,comp以ound 8b could induce SMMC-7721 cell apoptosis in a dose-dependent manner.Therefore,our novel findings may provide a new framework for the design of new 2-aminoimidazolone derivatives for the treatment of cancer.